- Liittynyt
- 17.8.2006
- ViestejÀ
- 16 338
Sargramostim ( Sargramostim is a man-made form of a protein that stimulates the growth of white blood cells in your body. White blood cells help your body fight against infection. Sargramostim is used in adults and children who are at least 2 years old, to help prevent serious infection in conditions such as leukemia , bone marrow transplant, and pre- chemotherapy blood cell collection.)
On 26 February 2021, the results from SARPAC (NCT04326920), an open-label, prospective, RCT of inhaled recombinant human Granulocyte-Macrophage Colony-Stimulating Factor (rhuGM-CSF or sargramostim) were announced. Among 81 patients with hypoxemic COVID-19 respiratory failure, oxygenation improved by at least 33% in 54% patients in the sargramostim plus standard care group versus by only 26% in the standard care only group (p=0.147) [48,49]. The results of the study have not yet been peer-reviewed.Several other agents have been studied for the pharmaceutical prophylaxis or treatment of COVID-19, but without any demonstrable clinical benefit.''
Colchicine
A double-blind RCT (COLCORONA) that enrolled 4 488 non-hospitalised COVID-19 patients with risk factors for severe disease showed that oral colchicine, a widely available anti-inflammatory agent, was associated with a decrease in the risk of hospitalisation or death from 6.0% to 4.6% (OR 0.75; 95% CI: 0.57â0.99; p=0.04) among the 4 019 patients with PCR-confirmed COVID-19. The results of this study have not yet been peer-reviewed [46]. On 22 January 2021, the Montreal Health Institute announced in a press release that colchicine decreased the risk of death or hospitalisation by 21% compared to placebo among 4 488 patients with COVID-19. The full results of this trial are not yet available [47].Preliminary results from a randomised, double-blind trial involving 4 488 non-hospitalised patients with COVID-19 being treated with colchicine showed a reduction in the composite rate of death or hospitalisation (OR 0.79; 95% CI, 0.61-1.03; p=0.08) [46].''
Budesonide
In a RCT of the inhaled corticosteroid budesonide in adults with mild COVID-19, the frequency of urgent care visits was 3% in the budesonide arm compared to 15% in the standard care arm (p=0.009) [23].Remdesivir
The interim results of the WHO Solidarity Trial, a RCT comparing four therapeutic agents to standard care carried out in 405 hospitals across 30 different countries, showed that remdesivir did not have any effect on mortality (relative risk (RR) 0.95; 95% CI: 0.81â1.11; p=0.50) [3]. The authors also did not observe any effect on the time to discharge, although the study was not designed to address this question. Based on a review of this and three other trials which, in total, studied more than 7 000 patients, a WHO Guideline Development Group (GDG) panel of international experts concluded that there is currently no evidence that remdesivir improves survival and other outcomes in hospitalised COVID-19 patients and issued a conditional recommendation against the use of remdesivir in these patients, regardless of disease severity [4].
Factsheet for health professionals on COVID-19
Factsheet on the COVID-19 pathogen, surveillance, clinical features, epidemiology, transmission, case management, and public health control measures.
wtf miksei vaan suoraan vankilaan